ERBB2 and breast cancer: Inhibition of HER2 using targeted inhibitors reduced SGLT1 expression in HER2+ breast cancer cells, while suppressing SGLT1 function using phlorizin or HER2 inhibitors led to a significant decrease in glycolytic activity with downregulation of PI3K/Akt/mTOR signalling, reducing breast cancer cell proliferation [100].